Inventiva (NASDAQ:IVA) and Bioxytran (OTCMKTS:BIXT) Head to Head Comparison

Inventiva (NASDAQ:IVA – Get Free Report) and Bioxytran (OTCMKTS:BIXT – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.

Insider & Institutional Ownership

19.1% of Inventiva shares are owned by institutional investors. 32.0% of Inventiva shares are owned by company insiders. Comparatively, 70.0% of Bioxytran shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk and Volatility

Inventiva has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, Bioxytran has a beta of 1.69, indicating that its share price is 69% more volatile than the S&P 500.

Profitability

This table compares Inventiva and Bioxytran’s net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Inventiva and Bioxytran”s gross revenue, earnings per share (EPS) and valuation.

Bioxytran has lower revenue, but higher earnings than Inventiva.

Analyst Ratings

This is a summary of current recommendations for Inventiva and Bioxytran, as provided by MarketBeat.

Inventiva currently has a consensus target price of $16.56, suggesting a potential upside of 384.93%. Given Inventiva’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Inventiva is more favorable than Bioxytran.

Summary

Inventiva beats Bioxytran on 7 of the 10 factors compared between the two stocks.

About Inventiva

(Get Free Report)

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

About Bioxytran

(Get Free Report)

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was founded in 2008 and is headquartered in Needham, Massachusetts.